Regeneron Pharmaceuticals, Inc. - 10-Q Summary (Q3 2009)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2009. Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products. Its primary commercial product is ARCALYST (rilonacept) for Cryopyrin-Associated Periodic Syndromes (CAPS). The company relies heavily on strategic collaborations with sanofi-aventis (for aflibercept and monoclonal antibodies) and Bayer HealthCare (for VEGF Trap-Eye) to fund research and development and share commercialization risks.
Key Financial Metrics
| Metric (in millions) | Q3 2009 | Q3 2008 | 9 Months 2009 | 9 Months 2008 |
|---|---|---|---|---|
| Total Revenues | $117.5 | $65.6 | $282.5 | $182.6 |
| Net Loss | $(1.0) | $(19.1) | $(31.3) | $(49.6) |
| Net Loss Per Share | $(0.01) | $(0.24) | $(0.39) | $(0.63) |
| Operating Expenses | $118.7 | $83.5 | $317.2 | $236.3 |
| Cash & Cash Equivalents | $250.3 | $247.8 | $250.3 | $314.7 |
| Total Liquid Assets (Cash, Restricted Cash, Marketable Securities) |
$438.6 | $527.5 | $438.6 | $527.5 |
| Facility Lease Obligation | $62.6 | $54.2 | $62.6 | $54.2 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 79% in Q3 2009 compared to Q3 2008. This was driven by a $20.0 million milestone payment from Bayer HealthCare for VEGF Trap-Eye and increased contract research revenue from sanofi-aventis.
- Improved Profitability: Net loss narrowed significantly to $1.0 million in Q3 2009 from $19.1 million in Q3 2008, primarily due to the milestone payment and higher collaboration revenues.
- Expense Increases: Research and Development (R&D) expenses rose to $105.4 million in Q3 2009 from $72.1 million in Q3 2008. This increase reflects higher clinical trial costs for VEGF Trap-Eye, ARCALYST (gout program), and monoclonal antibodies, as well as increased headcount.
- Accounting Revisions: The company revised previously issued financial statements to capitalize landlord construction costs for its Tarrytown facilities as a non-cash transaction, increasing Property, Plant, and Equipment and creating a corresponding Facility Lease Obligation. This had no impact on cash flows or net loss.
Guidance, Outlook, and Risks
- Clinical Pipeline:
- VEGF Trap-Eye: Phase 3 trials in wet AMD (VIEW 1 & 2) are fully enrolled; data expected late 2010. Phase 3 trials for Central Retinal Vein Occlusion (CRVO) initiated in Q3 2009.
- Aflibercept: Three Phase 3 oncology trials (colorectal, lung, prostate cancer) are >80% enrolled. A Phase 3 pancreatic cancer trial was discontinued in September 2009 due to lack of efficacy.
- ARCALYST: Phase 3 program for gout prevention and acute treatment is underway; initial data expected in H1 2010.
- Liquidity: The company holds $438.6 million in liquid assets. Management believes existing resources, including collaboration funding, will meet operating needs through at least 2012.
- Risks:
- Collaboration Dependence: Significant reliance on sanofi-aventis and Bayer HealthCare for funding and commercialization. Termination of these agreements would materially harm operations.
- Regulatory & Clinical Risk: High uncertainty regarding clinical trial outcomes and regulatory approvals for product candidates.
- Investment Portfolio: Risk of other-than-temporary impairment charges on marketable securities due to market volatility and credit quality deterioration.
Key Facts for Investor Verification
- Milestone Payment: Verify the recognition of the $20.0 million substantive milestone from Bayer HealthCare for the dosing of the first patient in the VEGF Trap-Eye CRVO Phase 3 trial.
- Sanofi-aventis Collaboration: Monitor the reimbursement rates and deferred revenue recognition related to the $105 million (aflibercept) and $85 million (antibody) up-front payments.
- Capital Expenditures: Review the $75.0 million in capital expenditures for the nine months ended Sept 30, 2009, primarily for tenant improvements at the new Tarrytown facilities.
- Accounting Changes: Confirm the impact of the FASB guidance revision regarding the Tarrytown lease, which capitalized $58.2 million in landlord construction costs.
- ARCALYST Sales: Track net product sales of $5.0 million for Q3 2009 and the projected $20 million in total shipments for 2009.